FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Andere talen Frazier Lifesciences Acquisition Corporation

Aandelen

NAMS

NL00150012L7

slotkoers Nasdaq Andere beurzen 00:00:00 15-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
19,81 ^EUR	-3,37%		-3,37%	+77,35%

15/05	FRAZIER LIFESCIENCES ACQUISITION CORPORATION : TD Cowen herhaalt koopadvies voor het aandeel	ZM
08/05	NewAmsterdam Pharma Company N.V. rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21/05
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21/05
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	09/05
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	09/05
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	01/04
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing	27/03
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	25/03
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	12/03
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd	12/03
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops	28/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Frazier Lifesciences Acquisition Corporation

Aandelen

NAMS

NL00150012L7

Andere talen

Filters